Remote monitoring in heart failure patients with cardiac amyloidosis yielded more alerts with high probability of cardiac decompensation than in those without (43.6% vs 25.7%, p<0.001).
Cohort (n=13,933)
Yes
Does remote monitoring with the Satelia Cardio program effectively identify cardiac decompensation in heart failure patients with cardiac amyloidosis compared to those without?
Remote monitoring in heart failure patients with cardiac amyloidosis effectively discriminates high-probability cardiac decompensation alerts, which occur more frequently than in heart failure patients without amyloidosis.
Absolute Event Rate: 43.6% vs 25.7%
p-value: p=<0.001
Abstract Introduction Heart failure (HF) remains a challenging condition to manage, particularly when complicated by conditions such as cardiac amyloidosis (CA). Innovations in remote monitoring technologies have the potential to revolutionize how these patients are managed by providing continuous data that can be used to adjust treatment regimens proactively. Objective The primary objective was to assess the characteristics of heart failure (HF) patients with cardiac amyloidosis (CA) monitored remotely with Satelia Cardio program. The secondary objective was to evaluate the discrimination of alerts by remote monitoring program for HF in this specific population. Method The entire multicentre cohort of HF patients monitored remotely with Satelia® Cardio program from August 2018 to December 2023 were included in the analysis. Results A total of 13,933 patients, including 346 (2.5%) with CA and 13,587 (97.5%) without cardiac amyloidosis (no-CA), had a median follow-up of 14 months. CA patients were more often male (78.6% vs 63.8%), over 80 years of age (69.9% vs 40.4%), with left ventricular ejection fraction 40% (78.6% vs 56.5%), more often NYHA class III-IV (26.6% vs 16.2%), more atrial fibrillation (54.0% vs 40.9%) but less myocardial infarction (8.4% vs 27.9%), diabetes (16.5% vs 28.1%), smoking (2.9% vs 13.4%), p0.001 for all. There was no difference in the rate of renal failure (21.7% vs. 20.3%), obstructive sleep apnea (15.9% vs. 14.9%) or stroke (10.7% vs. 9.4%). Remote monitoring identified a total of 57,624 alerts, including 1240 in the CA group vs 56,384 in the no-CA group (i.e. 3.58 alerts per CA patient vs 4.15 alerts per no-CA patient). Of the alert resolutions in the CA group vs no-CA group, 22.4% vs 38.9% had a low probability of cardiac decompensation, 34.0% vs 35.4% had a moderate probability, 43.6% vs 25.7% had a high probability of cardiac decompensation (global Chi-square p0.001). Conclusion Despite an elderly HF population with different comorbidities, remote monitoring with Satelia Cardio program in CA patients identifies correct relevance for discrimination of cardiac decompensation.
Mouhat et al. (Sat,) conducted a cohort in Heart failure with cardiac amyloidosis (n=13,933). Remote monitoring with Satelia Cardio program vs. Heart failure patients without cardiac amyloidosis was evaluated on Alert resolutions with a high probability of cardiac decompensation (p=<0.001). Remote monitoring in heart failure patients with cardiac amyloidosis yielded more alerts with high probability of cardiac decompensation than in those without (43.6% vs 25.7%, p<0.001).